TrialAnnals of oncology : official journal of the European Society for Medical Oncology2014

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.

J V Heymach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.